title: Effect of antihypertensive treatment on the increased beta 2-adrenoceptor density in patients with essential hypertension.
abstract: The effect of different antihypertensive drugs on the increased surface beta 2-adrenoceptor density in essential hypertension was evaluated to elucidate whether the possible effect of the treatment on these receptors was secondary to blood pressure decreases or a specific effect of the drugs. Thirty-nine untreated essential hypertensive patients and 28 normotensive control subjects were studied in basal conditions. Hypertensive patients were randomly assigned to three treatment groups: bisoprolol (10 mg/day, n = 15), enalapril (20 mg/day, n = 12), and verapamil SR (240 mg/day, n = 12), and were studied before and after 1 month of treatment. Plasma catecholamines were determined by a radioenzymatic assay. Surface beta 2-adrenoceptors were measured in intact lymphocytes by radioligand binding assay using the hydrophilic ligand [3H]-CGP12177. beta 2-adrenoceptor density was increased in hypertensive patients (P < .01). After treatment, mean blood pressure decreased similarly in the three groups, while plasma catecholamines showed no significant changes in any group. beta 2-adrenoceptor number decreased only in bisoprolol-treated patients (P < .05). Mean blood pressure decreases correlated with beta 2-adrenoceptor decrements only in bisoprolol-treated patients (r = 0.65, P < .05). beta 2-adrenoceptor density correlated with plasma epinephrine levels in the control group (r = -0.50, P < .01), but not in hypertensive patients before treatment. This correlation was also observed in hypertensive patients treated with bisoprolol (r = -0.52, P < .05), but not in those treated with verapamil or enalapril. Our results suggest that bisoprolol treatment reduces the increased surface beta 2-adrenoceptor density and restores its regulation by epinephrine in essential hypertension.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Nephrology Units, Hospital Clinic I Provincial, Barcelona, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Bono
authors.forename: A
authors.initials: A
authors.lastname: Cases
authors.forename: J
authors.initials: J
authors.lastname: Calls
authors.forename: J
authors.initials: J
authors.lastname: Gaya
authors.forename: W
authors.initials: W
authors.lastname: Jiménez
authors.forename: J
authors.initials: J
authors.lastname: Carretero
authors.forename: F
authors.initials: F
authors.lastname: Rivera
authors.forename: L
authors.initials: L
authors.lastname: Revert
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D015992:Body Mass Index; D002395:Catecholamines / Q000097:blood; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy*; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D008297:Male; D011869:Radioligand Assay; D018343:Receptors, Adrenergic, beta-2 / Q000187:drug effects* / Q000378:metabolism
chemical_list: D000959:Antihypertensive Agents; D002395:Catecholamines; D018343:Receptors, Adrenergic, beta-2